{
  "kind": "framework",
  "value": "waterfall-plot",
  "collectionKey": "slides:framework:waterfall-plot:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 5,
  "page": 1,
  "pageSize": 24,
  "pageCount": 1,
  "rows": [
    {
      "docId": "019de074-2e24-777e-87b3-831358a7e33a",
      "docSlug": "971513439f6499291689438a6a6dd75f",
      "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 20 slides",
      "authorId": "compass-therapeutics",
      "authorName": "Compass Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard oncology clinical trial visualization for tumor response",
      "slideHref": "/slides/019de074-2e24-777e-87b3-831358a7e33a/6",
      "deckHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a",
      "deckAnchorHref": "/decks/019de074-2e24-777e-87b3-831358a7e33a#slide-6",
      "loopMatches": [
        {
          "to": 8,
          "from": 6,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "044654bc-2486-4078-b913-f66936c4244b",
          "evidence": "Slides 6-8 present clinical trial data, implying that not investing could mean missing out on a potentially effective treatment.",
          "position": 0,
          "objective": "What are the consequences of not investing in CTX-009?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 8,
          "from": 3,
          "beatId": "d33bd1e8-59e3-4285-9fff-5d07e1436828",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Product",
          "beatSlug": "sequoia-pitch-product",
          "evidence": "Slides 3-8 detail the product, CTX-009, and its clinical trial data.",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
      "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
      "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
      "authorId": "compass-therapeutics",
      "authorName": "Compass Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-05-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The chart is a classic waterfall plot used in oncology to demonstrate drug efficacy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard oncology clinical trial visualization",
      "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/17",
      "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
      "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-e431-717d-85d5-60fbb8c86744",
      "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
      "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
      "authorId": "nuvalent",
      "authorName": "Nuvalent",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-02-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard oncology clinical trial visualization",
      "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/20",
      "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
      "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-20",
      "loopMatches": [
        {
          "to": 20,
          "from": 17,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "768b9693-f057-40a9-8283-be0c1cfc71ac",
          "evidence": "The deck presents data on the cost of inaction for cancer patients and how Nuvalent's solution addresses this",
          "position": 1,
          "objective": "What is the cost of inaction for cancer patients and how does Nuvalent's solution address this?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.6,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 36,
          "from": 17,
          "beatId": "af664db1-d363-4d9c-b782-ebd7f300239a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Traction",
          "beatSlug": null,
          "evidence": "The deck presents traction and clinical trial data from slides 17 to 36",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": null,
          "parentBeatSlug": null
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
      "docSlug": "a9cc0c508d45d8985f57408ace49b969",
      "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
      "authorId": "rayzebio",
      "authorName": "RayzeBio",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investment_bank",
      "sourceTypeLabel": "Investment bank",
      "presentationDate": "2023-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7761332,
      "pageNumber": 18,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial efficacy visualization",
      "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/18",
      "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
      "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-18",
      "loopMatches": [
        {
          "to": 21,
          "from": 16,
          "name": "Hypothesis Test",
          "slug": "42-hypothesis-test",
          "bestFor": "Strategy validation, due diligence, research presentations",
          "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5",
          "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.",
          "position": 2,
          "objective": "How does RYZ101 perform in clinical trials?",
          "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
          "confidence": 0.7,
          "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 20,
          "from": 15,
          "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Solution",
          "beatSlug": "sequoia-pitch-solution",
          "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de073-98a7-740c-b2bf-3eb3f25491f5",
      "docSlug": "adb5c4514a6016378ffb63c7d4422971",
      "documentTitle": "TCR2 Therapeutics | Results Presentation Deck | 34 slides",
      "authorId": "tcr2-therapeutics",
      "authorName": "TCR2 Therapeutics",
      "documentKindSlug": "regulatory-filing",
      "documentKindLabel": "Regulatory filing",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2022-09-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Waterfall plot is a standard clinical trial visualization for tumor response.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": "Standard clinical trial visualization for tumor response",
      "slideHref": "/slides/019de073-98a7-740c-b2bf-3eb3f25491f5/18",
      "deckHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5",
      "deckAnchorHref": "/decks/019de073-98a7-740c-b2bf-3eb3f25491f5#slide-18",
      "loopMatches": [
        {
          "to": 18,
          "from": 8,
          "name": "Jobs To Be Done",
          "slug": "53-jobs-to-be-done",
          "bestFor": "Product innovation, market entry, competitive positioning",
          "matchId": "0a2012e0-6a06-4e15-803c-e8ae832be1d6",
          "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
          "position": 1,
          "objective": "How can TRuC-T cell therapy address the needs of patients with solid tumors?",
          "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
          "confidence": 0.7,
          "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 18,
          "from": 8,
          "beatId": "fd7bc9b8-ed02-40c1-b1d1-66cb54ef449d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "The document presents TRuC-T cell therapy as a solution, showcasing Phase 1 trial results.",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}